Apnimed, Inc. (APMD) News
Track canonical SquawkNews coverage tagged to APMD, Apnimed, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Apnimed Q2 2026 net income $125.9M; Oxnimbi PDUFA Feb 28, 2027
Apnimed reported Q2 2026 net income of $125.9M and ended the quarter with $172.8M in cash and cash equivalents. FDA accepted its NDA for AD109 (proposed Oxnimbi) with a PDUFA target date of Feb 28, 2027.
EARNINGS | Sep 08, 2026, 09:23 PM UTC
M
APMD net income rises to $193.7M in H1 2026
APMD reported net income of $193.7M for the first half of 2026, driven by SASS divestiture gains. R&D expenses fell as Phase 3 trials for Oxnimbi concluded. Cash was $172.8M pre-IPO and $200.4M raised in August.
EQUITY | Sep 08, 2026, 09:16 PM UTC
M
Apnimed posts 2Q net $125.9M
Apnimed reported 2Q net income of $125.9M.
EQUITY | Sep 08, 2026, 08:40 PM UTC
L
Apnimed reports Q2 2026 financial results and corporate update
Apnimed (APMD) reports second-quarter 2026 financial results and provides a corporate update.
EARNINGS | Sep 08, 2026, 08:39 PM UTC
L
Apnimed reports inducement grants under Nasdaq Rule 5635(c)(4)
Apnimed, Inc. reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:01 PM UTC
M
Apnimed Closes Upsized IPO
Apnimed closes upsized initial public offering
EQUITY | Aug 03, 2026, 08:35 PM UTC
L
APMD APMD - Apnimed Announces Pricing of Upsized Initial Public Offering
APMD APMD - Apnimed Announces Pricing of Upsized Initial Public Offering
EQUITY | Jul 31, 2026, 02:10 AM UTC